Year: 2012
Type: article
Study design: Observational Study
Abstract: The application of paired-end next generation sequencing approaches has made it possible to systematically characterize rearrangements of the cancer genome to base-pair level. Utilizing this approach, we report the first detailed analysis of ovarian cancer rearrangements, comparing high-grade serous and clear cell cancers, and these histotypes with other solid cancers. Somatic rearrangements were systematically characterized in eight high-grade serous and five clear cell ovarian cancer genomes and we report here the identification of > 600 somatic rearrangements. Recurrent rearrangements of the transcriptional regulator gene, TSHZ3, were found in three of eight serous cases. Comparison to breast, pancreatic and prostate cancer genomes revealed that a subset of ovarian cancers share a marked tandem duplication phenotype with triple-negative breast cancers. The tandem duplication phenotype was not linked to BRCA1/2 mutation, suggesting that other common mechanisms or carcinogenic exposures are operative. High-grade serous cancers arising in women with germline BRCA1 or BRCA2 mutation showed a high frequency of small chromosomal deletions. These findings indicate that BRCA1/2 germline mutation may contribute to widespread structural change and that other undefined mechanism(s), which are potentially shared with triple-negative breast cancer, promote tandem chromosomal duplications that sculpt the ovarian cancer genome.
Source: The Journal of Pathology
DOI: 10.1002/path.4042
Authors: David J McBride, Dariush Etemadmoghadam, Susanna L Cooke, Kathryn Alsop, Joshy George, Adam Butler, Juok Cho, Danushka Galappaththige, Chris Greenman, Karen D Howarth, King W Lau, Charlotte K Ng, Keiran Raine, Jon Teague, David C Wedge, Australian Ovarian Cancer Study Group, Xavier Caubit, Michael R Stratton, James D Brenton, Peter J Campbell, P Andrew Futreal, David DL Bowtell
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,450
Funders: Wellcome Trust, Cancer Research UK, National Institute for Health and Care Research, University of Cambridge, Royal Adelaide Hospital, Townsville Hospital and Health Service, Medical Research Council, National Health and Medical Research Council, Cancer Council Tasmania, Medical Research and Materiel Command
OpenAlex ID: W2161915993
